Tejas: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
Study Details
Study Description
Brief Summary
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
A Two Stage Phase 2 Study: Stage 1: Single Subcutaneous Dose Open-label Assessment of Safety and Pharmacodynamic Response to D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME). Stage 2: Visual Examiner-Masked, Randomized Active, Sham and Placebo Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Subcutaneously Administered D-4517.2 to Subjects with Neovascular (wet) Age-Related Macular Degeneration
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Neovascular Age-related Macular Degeneration Cohort A1 - 0.25 mg/kg of D-4517.2 Cohort B1 - 0.5 mg/kg of D-4517.2 |
Drug: D-4517.2
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
|
| Experimental: Diabetic Macular Edema Cohort A2 - 0.25 mg/kg of D-4517.2 Cohort B2 - 0.5 mg/kg of D-4517.2 |
Drug: D-4517.2
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
|
Outcome Measures
Primary Outcome Measures
- Number of participants with Treatment-Emergent Adverse Events [Safety] [Safety and tolerability of a single SC dose of D-4517.2 at 26 weeks]
Safety of single dose of D-4517.2 as measured by treatment-related adverse events as assessed by CTCAE v5.0
Secondary Outcome Measures
- Number of participants with a reduction in sub-retinal fluid after a single intravitreal (IVT) dose of aflibercept and a single SC dose of D-4517.2 [Within subject, percent reduction in subretinal fluid volume in study eye after IVT aflibercept and D-4517.2 at 2, 4, 6, 8, and 12 weeks post-dose measured by spectral domain optical coherence tomography (SD-OCT).]
Change in sub-retinal fluid as measured by spectral domain optical coherence tomography (SD-OCT).
- Number of participants with duration of effect of D-4517.2 as assessed by changes in subretinal fluid over time up to 12 weeks [Within subject, central subfield thickness (CST) in study eye after IVT aflibercept and D-4517.2 at 2, 4, 6, 8, and 12 weeks post-dose as assessed by SD-OCT.]
Effect of D-4517.2 as measured by spectral domain optical coherence tomography (SD-OCT).
- Number of participants with Ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) observed for D-4517.2 and aflibercept [By dose level, mean difference in percent reduction in subretinal fluid in study eye after IVT aflibercept and D-4517.2 at 2, 4, 6, 8, and 12 weeks post-dose as measured by SD-OCT.]
Participants with ocular and non-ocular adverse events and serious adverse events as measured by CTCAE v5.0
- Number of participants with change in best corrected visual acuity (BCVA) in study eye after each treatment (aflibercept or D-4517.2). [Change from baseline in BCVA in study eye as assessed by early treatment of diabetic retinopathy scale (ETDRS) after each treatment (aflibercept and D-4517.2) at 4, 6, 8, and 12 weeks post-dose.]
Participants with change in vision as measured best corrected visual acuity (BCVA) assessment.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Overall Study Inclusion Criteria-For All Subjects:
-
Willing and able to give informed consent, comply with all study procedures, and be likely to complete the study.
-
Demonstrated response to prior anti-VEGF treatment since diagnosis as defined by one or more of the following:
-
Reduction of subretinal fluid or intraretinal fluid of greater than equal to 30% from initial diagnosis as measured by SD-OCT.
-
Elimination of prior sub-foveal fluid from initial diagnosis as measured by SD-OCT.
-
Increase in BCVA of greater than or equal to 2 lines from initial diagnosis using Snellen scale.
-
Female subjects may be enrolled if they are:
-
Not pregnant, lactating, or breastfeeding
-
Documented to be surgically sterile or postmenopausal.
-
Female subjects of childbearing potential must practice true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days after the last IP administration and have a negative serum and urine pregnancy test at Screening and Baseline Day 1, respectively, or
-
Using 2 forms of highly effective contraception, including 1 physical barrier (condom or diaphragm) plus another method, such as adequate hormonal method (eg, contraceptive implants, injectables, or oral contraceptives) or nonhormonal methods (eg, intrauterine device or spermicidals) from Screening or at least 2 weeks prior to IP administration (whichever is earlier) until 30 days after the last IP administration and having a negative serum and urine pregnancy test at Screening and Baseline Day 1, respectively.
-
Male subjects with female partners of childbearing potential may be enrolled if they are:
-
Documented to be surgically sterile (vasectomy), or
-
Practicing true abstinence for 30 days after the last IP administration, or
-
Using 2 adequate forms of highly effective contraception, 1 of which should be a physical barrier for 30 days after the last IP administration.
-
Must agree not to donate sperm during study and for 30 days following administration of the last dose of IP.
Subjects With Wet AMD (For Both Stage 1 and Stage 2):
-
Male or nonpregnant female adults aged ≥50 years at time of signing the informed consent form (ICF).
-
BCVA letter score between 75 and 23 letters (ETDRS chart) (20/32 to 20/320 Snellen equivalents) inclusive in the study eye at baseline and BCVA letter score of at least 35 letters ETDRS chart (20/200 Snellen equivalent) in the non-study eye.
-
Presence of a choroidal neovascular (CNV) lesion secondary to AMD treated with at least 3 and no more than 9 prior IVT injections of an anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab) with last treatment between 4 and 12 weeks prior to Screening. Administration of IVT anti-VEGF agents prior to enrollment must not be more than 12 weeks apart.
-
Decrease in vision in the study eye determined by Investigator to be primarily the result of exudation from wet AMD.
-
Ocular media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus imaging.
-
Recurrence of subretinal fluid or increase in CST at study entry.
-
For subjects with bilateral disease, only one eye per subject is eligible to participate in the study. In cases where both eyes are eligible, the eye with the worse BCVA at the Screening Visit will be selected as the study eye. If both eyes have the same BCVA, the decision of which eye to select as the study eye will be made by the Investigator.
Subjects With DME ( For Stage 1 Only):
-
Male or nonpregnant female adults aged ≥18 years at time of signing the ICF.
-
BCVA letter score between 75 and 23 letters (ETDRS chart) (20/32 to 20/320 Snellen equivalents) inclusive in the study eye at baseline.
-
Diagnosis of diabetes mellitus (Type 1 or Type 2). Any of the following will be considered to be sufficient evidence that diabetes is present:
-
Current regular use of oral anti-hyperglycemic agents for the treatment of diabetes.
-
Current regular use of insulin or other injectable drugs (eg, dulaglutide and liraglutide) for the treatment of diabetes.
-
Documented diabetes by American Diabetic Association (ADA) and/or World Health Organization (WHO) criteria.
-
Hemoglobin A1c (HbA1c) ≤12% (historic values up to 3 months before Screening Visit will be permissible, otherwise study site may collect sample for analysis at Screening).
-
DME defined as macular thickening by SD-OCT involving the center of the macula. A CST of ≥350 μm with Spectralis® (Heidelberg Engineering, Heidelberg, Germany) at Screening.
-
Recurrence of subretinal fluid or increase in CST criteria prior to treatment.
-
The cause of the decreased vision in the study eye has been attributed primarily to DME by the Investigator.
-
History of previous treatment in the study eye with at least 3 and no more than 9 prior injections with anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab) with last treatment between 4 and 12 weeks prior to Screening. Administration of IVT anti-VEGF agents prior to enrollment must not be more than 12 weeks apart.
-
Ocular media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus imaging.
-
For subjects with bilateral disease, only one eye per subject is eligible to participate in the study. In cases where both eyes are eligible, the eye with the worse BCVA at the Screening Visit will be selected as the study eye. If both eyes have the same BCVA, the decision of which eye to select as the study eye will be made by the Investigator.
Exclusion Criteria:
- Medical Conditions:
-
History, within 6 months prior to Screening, of any of the following: myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, transient ischemic attack, or stroke
-
Uncontrolled hypertension with systolic BP ≥160 mmHg and/or diastolic BP ≥95 mmHg (while patient at rest) at the Screening Visit. If the patient's initial reading exceeds these values, a second reading may be taken 30 minutes later on the same day. If the patient's BP is controlled by antihypertensive medication, the patient should be taking the same medication continuously for at least 30 days prior to Day 1.
-
Currently untreated diabetes mellitus or previously untreated subjects who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1.
-
Uncontrolled diabetes mellitus as defined by HbA1c >12%.
-
Chronic renal disease requiring chronic hemodialysis or renal transplantation.
-
Abnormal liver function, as defined by transaminase or total bilirubin 2 times above the upper limit of normal at the Screening Visit.
-
Medical history of Wolff-Parkinson-White Syndrome, family history of long QT, or on medication prolonging QT time or planned initiation during the trial.
-
Known allergy to constituents of the study drug formulation, aflibercept, or clinically relevant hypersensitivity to fluorescein used by the patient during the study.
-
Serious systemic infection:
-
Any active infection for which systemic anti-infectives were used within 4 weeks before randomization.
-
Recurrent or chronic infections or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
-
Any organic or psychiatric disorder, or laboratory abnormality which, in the opinion of the Investigator, will prevent the patient from completing the study activities as in the protocol or interfere with the interpretation of the study results.
-
An underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) or history of other disease, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study drug, might affect interpretation of the results of the study or which, in the opinion of the Investigator, renders the patient at unacceptable risk of treatment complications by participating in the trial
-
Any major illness or surgical procedure within 1 month before Screening
-
History of other diseases, physical examination finding, historical or current clinical lab finding giving reasonable suspicion of condition that contraindicates the use of the IP or that might affect the interpretation of the results of the study or renders the patient at high risk for treatment complications, in the opinion of the Investigator.
-
Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or HIV type 1 and 2 antibodies.
Prior/Concomitant Therapy:
-
Participation in any investigational study within 30 days prior to Screening, or planned use of an IP or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives).
-
Chronic alcohol or drug abuse or any condition that, in the Investigator's opinion, makes them an unreliable study participant or unlikely to complete the trial.
-
Use of systemic medications known to be toxic to the lens, retina or optic nerve (eg, deferoxamine, chloroquine/hydroxy-chloroquine, tamoxifen, phenothiazines, and ethambutol) used during the 6 month or 5 half-lives (whichever is longer) prior to Day 1 or likely need to be used.
-
Use of systemic immunomodulatory treatments (eg, interleukin-6 inhibitors) within 6 months or 5 half-lives (whichever is longer) prior to Day 1.
-
Use of systemic corticosteroids within 1 month prior to Day 1.
-
Systemic treatment for suspected or active systemic infection.
-
Administration of systemic anti-VEGF or pro-VEGF treatment within 180 days or 5 half-lives, whichever is longer, before randomization visit.
-
Any prior concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives, whichever is longer, before randomization visit.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical Center Ophthalmology Associates - Northwest | San Antonio | Texas | United States | 78240 |
Sponsors and Collaborators
- Ashvattha Therapeutics, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D-4517-002